NeuroNOS is excited to share the BIG news from the #FDA! The #FDA granted us an Orphan Drug Designation for #PhelanMcDermidSyndrome, a Neurodevelopmental Disorder Linked to #Autism #OrphanDrug #NitricOxide #PMS #RareDisease nasdaq.com/press-release/…

🎧 Prof. Haitham Amal - Amal Lab, CSO @NeuroNOS, explains how NO dysregulation drives Phelan‑McDermid Syndrome (PMS) & how our FDA‑orphan small molecule advances to first‑in‑human trials in 2026. Watch ▶️ youtube.com/watch?v=YdKiIA… #PMSF #CureSHANK #RareDisease #Autism #DrugDiscovery

We're honored to be highlighted by @brainfdn for our work on nitric oxide modulation in #autism. Proud to share the science — and the stage — at #Synchrony2025. linkedin.com/feed/update/ur… #NeuroNOS #NitricOxide #TranslationalResearch #ASD #CNS #DrugDevelopment

🔙 #ThrowbackThursday: 2023 Adv Sci paper “The NO answer for ASD” showed that nitric‑oxide modulation can reverse autism‑like behavior 👉 advanced.onlinelibrary.wiley.com/doi/full/10.10… @NeuroNOS is turning that insight into a first‑in‑human nNOS small‑molecule trial in 2026. #NO #Autism #ASD

Proud to share that our CSO, Prof. Haitham Amal - Amal Lab Amal, joins the #Synchrony2025 Roundtable on neuroenergetics in autism. Excess NO → oxidative stress → mitochondrial strain. Our nNOS-targeted small molecule aims to restore balance. #NO #Autism linkedin.com/posts/the-brai…

📽️Sneak peak: We spoke with three world-class scientists, joined by our two extraordinary Nobel Laureates who serve on our Scientific Advisory Board (SAB), as well as our CSO, to discuss our novel small-molecule nitric oxide inhibition platform for autism. #NobelPrize #Autism

Lifetime autism care may exceed $4M per person (Zhao et al., 2024). Most treatments manage symptoms, few target root biology. At NeuroNOS, we’re developing a first-in-class drug to rebalance NO signaling in ASD. #NeuroNOS #Autism #ASD #NitricOxide #HealthEconomics

#ThrowbackThursday: A 2022 Free Radical Biology & Medicine paper by Haitham Amal - Amal Lab revealed how nitric oxide disrupts NMDA receptor signaling in ASD models. At NeuroNOS, we’re targeting that biology with our selective nNOS inhibitor. #ASD #NitricOxide #TBT Elsevier

Nitric oxide (NO) is vital in balance, too much from nNOS fuels nitrosative stress, disrupting synapses. Research by our CSO, Prof. Haitham Amal - Amal Lab, links this to ASD. At NeuroNOS, we’re developing a selective nNOS inhibitor to restore brain balance. #ASD #BrainHealth #NitricOxide

#ThrowbackThursday: Prof. Haitham Amal - Amal Lab’s lab (our CSO) found disrupted autophagy proteins in two ASD models, driven by NO imbalance. Blocking nNOS restored normal function—reinforcing NeuroNOS’s approach to rebalance NO & tackle core ASD biology. #AutismResearch #NeuroNOS

We’re proud our CSO, Prof. Haitham Amal - Amal Lab, will speak at #Synchrony2025 on Aug 22! His nitric oxide work shapes our mission at NeuroNOS. Thanks to the BRAIN foundation, Boston Children's, Hebrew University, and the Rosamund Stone Zander Center for advancing this dialogue #AutismResearch

In a landmark Redox Biology review, our CSO Prof. Haitham Amal - Amal Lab (@NeuroNOS) with Tripathi & Kartawy highlighted how NO dysregulation drives brain disorders. We’re building on these insights with a selective nNOS inhibitor for ASD. Elsevier #NeuroNOS #AutismResearch #NitricOxide

Glioblastoma (GBM) is the most aggressive brain cancer, with survival often measured in months despite current treatments. At NeuroNOS, we’re developing a novel nNOS inhibitor to rebalance nitric oxide signaling that fuels tumor growth. #NeuroNOS #Glioblastoma #braincancercure

(Nasdaq: $XAIR) NeuroNOS , a Beyond Air subsidiary, has been granted FDA Orphan Drug Designation for BA-101 in glioblastoma, one of the deadliest brain cancers. With few advances in treatment in decades, BA-101’s nitric oxide modulation approach could represent a breakthrough

Proud to share: the FDA has granted Orphan Drug Designation to BA-101 for Glioblastoma (GBM) — the most common malignant brain cancer in adults. This is our 2nd ODD in 2025, advancing our mission to deliver targeted nitric-oxide–modulating therapies. stocks.apple.com/AiEjITBE8QwCR7…